Agenus Inc.

NasdaqCM:AGEN

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💉 Vaccines

Location

United States

Market Cap

USD 122.55 M

Share Price

USD 4.47

Avg Daily Volume

932,039

Change (1 day)

-6.49%

Change (1 year)

-65.59%

Change (YTD)

63.14%

Agenus Inc. Revenue for the Trailing 12 Months (TTM) ending March 31, 2025: USD 99.52 M

Agenus Inc. Revenue is USD 99.52 M for the Trailing 12 Months (TTM) ending March 31, 2025, a -38.34% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Agenus Inc. Revenue for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 161.42 M, a 69.94% change year over year.
Agenus Inc. Revenue for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 94.99 M, a -69.35% change year over year.
Agenus Inc. Revenue for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 309.89 M, a 265.60% change year over year.
Agenus Inc. Revenue for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 84.76 M, a -0.61% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue	Revenue	Gross Profit	Operating Income

NasdaqCM: AGEN

Agenus Inc.

CEO	Dr. Garo H. Armen Ph.D.
IPO Date	Feb. 8, 2000
Location	United States
Headquarters	3 Forbes Road
Employees	316
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💉 Vaccines

Description

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.